Manhattan BioSolutions Enters into Evaluation and Potential Licensing Agreement with Biocytogen for Use of Innovative Antibodies in Targeted Therapies
New York City, New York and Beijing, China, January 3, 2023 – Manhattan BioSolutions, Inc. (Manhattan Bio or MABS), an emerging biotech company developing innovative…
Read more
Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02
Beijing, China and Shanghai, China, December 27, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and CtM Biotech (Shanghai) Co., Ltd ("CtM Bio")…
Read more
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences
Beijing, China and San Diego, US, December 19, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd (“Biocytogen”, HKEX: 02315) today announced that it has entered into…
Read more
Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors
Beijing, China and Barcelona, Spain, December 18, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery…
Read more
Biocytogen Secures U.S. Patent for Key Technology of the Fully Human Antibody Mouse (RenMab) Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) is pleased to announce that the company has been granted a patent from the United States Patent…
Read more
SITC 2023 Highlights: Biocytogen’s Novel Assets and Products
The Biocytogen team concluded a successful SITC 2023 event, after presenting 9 drug asset posters, 7 genetically engineered mouse model posters, and connecting with current…
Read more
Biocytogen Officially Launches RenMice® Series
Fully Human Antibody and TCR Mouse Models Showcase Biocytogen's Capabilities to Innovate the Discovery of Novel Biologic Drugs Beijing, China, September 15, 2023 – Biocytogen…
Read more
Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development
Beijing, China, September 7, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody…
Read more
Biocytogen Establishes Two Business Divisions to Distinguish Preclinical Models and Services (BioMice) From Antibody Drug R&D
Beijing, China, August 31, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to…
Read more
Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies
BEIJING, China, August 30, 2023 – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), announced today…
Read more